natgillin/translations-raw huggingface dataset:
14, 15 or 16, wherein the scFab is coupled to a C-terminal end of the CH2-CH3 Ig entity by the linker and wherein the brain effector entity is selected from the group consisting of neurological disorder drugs, neurotrophic factors and antibody fragments directed to a brain target selected from the group consisting of scFv, Fv, scFab, Fab, VHH, F(ab')2 or peptides directed to a brain target and wherein the brain target is selected from the group consisting of B-secretase 1, AB, epidermal growth factor, epidermal growth factor receptor 2, Tau, phosphorylated Tau, apolipoprotein E4, alpha synuclein, oligomeric fragments of alpha synuclein, CD20, huntingtin, prion protein, leucine rich repeat kinase 2, parkin, presenilin 2, gamma secretase, death receptor 6, amyloid precursor protein, p75 neurotrophin receptor and caspase 6. 
14, 15 ili 16, pri čemu je scFab spojen s C-terminalnim krajem entiteta CH2-CH3-Ig putem povezivača, te time, da je entitet moždanog efektora odabran iz HR P20191153T1 skupine koja se sastoji od lijekova za liječenje neuroloških poremećaja, neurotrofičnih faktora te fragmenata protutijela usmjerenih na moždani cilj, odabranih iz skupine koja se sastoji od scFv, Fv, scFab, Fab, VHH, F(ab'), ili peptida usmjerenih na moždani cilj, te je pritom moždani cilj odabran iz skupine koja se sastoji od B-sekretaze 1, Af, faktora epidermalnog rasta, receptora faktora epidermalnog rasta 2, Tau, fosforiliranog Tau, apolipoproteina E4, alfa sinukleina, oligomernih fragmenata alfa sinukleina, CD20, huntingitina, prionskog proteina, kinaze 2 bogate ponavljajućim leukinom, parkina, presenilina 2, gama sekretaze, receptora smrti 6, proteina amiloidnog prekursora, receptora neutrofina p75 i kaspaze 6.
The apparatus according to Claims 9, characterized in that the passage is a sluice. 
Uređaj prema Zahtjevu 9, naznačen time da je prolaz prolaz za tlak.
The nonwoven wipe according to claim 1, wherein exterior surfaces of the bonded portions are recessed relative to exterior surfaces of the unbonded portions at each of the opposite faces of the nonwoven wipe. 
Netkani materijal prema zahtjevu 1, naznačen time da su vanjske površine spojenih dijelova udubljene u odnosu na vanjske površine nespojenih dijelova na svakom od nasuprotnih lica netkanog materijala.
Measurement of the Total Organic Carbon (TOC) 
Analitički postupci 2.1.Mjerenje ukupnog organskog ugljika (TOC)
This objective is achieved according to the present invention by a mini-gastrin analogue PP-F11 having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y stands for an amino acid replacing methionine and X stands for a chemical group attached to the peptide for the purpose of diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. 
Analog mini-gastrina PP-F11, naznačen time, da je predstavljen sljedećom formulom: PP-F1 1: X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y -Asp-Phe-NH>, pri čemu Y predstavlja aminokiselinu koja zamjenjuje metionin, i X predstavlja kemijsku skupinu koja je priključena na peptid u svrhu dijagnostičke i/ili terapeutske intervencije kod odgovarajućih bolesti vezanih uz CCK2-receptor.
The juice extraction module according to claim 10, wherein a bottom region of the input portion is positioned to be offset within a semicircle region of a circle having a diameter corresponding to a diameter of the crushing processing portion with a central shaft of the screw as a center. 
Modul za ekstrakciju soka u skladu s patentnim zahtjevom 10, naznačen time što je donje područje dijela za ubacivanje (410) tako smješteno da bude ekscentrično unutar polukružnog područja kruga čiji promjer odgovara promjeru dijela za obradu drobljenjem (600) sa središnjom osovinom (310) vijka (300) u središtu.
is hydrogen or C1-C6 alkyl wherein the alkyl is optionally substituted with halo. 
je vodik ili C1-C6alkil gdje je alkil po izboru supstituiran sa halogenom,
the non-naturally encoded amino acid is a phenylalanine analog or derivative that is optionally linked to a linker, polymer, water soluble polymer, or biologically active molecule. 
ne-prirodno kodirana aminokiselina je para-acetil-fenilalanin koja je po izboru povezana sa veznikom, polimerom, polimerom topivim u vodi, ili biološki aktivnim molekulom.
A support means according to claim 18 wherein the movement of the containers and support means is such as to cause movement of a gas filled space within each of the containers, through the foodstuff in the container. 
Držač prema zahtjevu 18 gdje je kretanje spremnika i držača takvo da uzrokuje kretanje zraka unutar svakog spremnika kroz prehrambeni proizvod koji se nalazi u spremniku,
The process according to claim 1, wherein the acid has a pKa at 25° C. of from 0 to 2.5. The process according to claim 9, wherein the acid is H2SO3, HSO4−, H3PO4, oxalic acid, or mixtures thereof. 
Postupak prema zahtjevu 4, pri čemu kiselina ima pK, pri 25*C od 0 do 2.5, te je preporučeno H2SO;, HSOy, H;PO., oksalna kiselina, ili njihova smjesa.
These and other modifications, which will be apparent to those skilled in the art, should be considered within the spirit and scope of the following claims. 
Ove i druge modifikacije, što je očito stručnjacima u ovom području, se trebaju razmatrati unutar opsega sljedećih patentnih zahtjeva.
an antibody light chain comprising an antibody light chain sequence of SEQ ID NO: 35 or a variant thereof; and 
(11) lakog lanca čija sekvenca odgovara sekvenci lakog lanca antitijela izabranoj iz grupe koju čine SEQ ID NO:
The bispecific antibody or antibody fragment thereof of claim 12, wherein the second component is a cell-binding agent, a cytotoxic agent, a radioisotope, an enzyme substrate, a fluorophore, a chromophore, an imaging agent or a metal ion. 
Uporaba protutijela ili fragmenta protutijela prema bilo kojem od zahtjeva 1 do 5 naznačena time da je za istraživanje ili in vitro dijagnostičke primjene, pri čemu navedeno protutijelo ili fragment protutijela sadrži oznaku kao što je radioaktivna oznaka, fluorofora, kromofora, sredstvo za slikanje ili metalni ion.
Thus, in one aspect the present invention relates to a method for the synthesis of Y,δ-dihydroxyisoleucine 1, or of a synthon for compound 1, comprising the step of methylating compound 3, particularly with methyl iodide in the presence of lithium bis(trimethylsilyl)amide (LHMDS). 
PATENTNI ZAHTJEVI 1. Postupak sinteze y,O-dihidroksiizoleucina 1, ili sintona spoja 1, naznačen time, da obuhvaća korak metilacije spoja 5 3 ili 3* s metil jodidom u prisutnosti litij bis(trimetilsilil)amida (LHMDS).
A tabletting tool with top punch, bottom punch and die for tablets with a diameter of 10 mm and a radius of curvature of 8 mm was heated to 80° C. in a heating cabinet. 
Alat za tabletiranje s gornjim kalupom, donjim kalupoma i matricom za tablete s promjerom od 10 mm i radijusom zaobljenosti od 8 mm je zagrijan u komori za zagrijavanje na 80C.
The method of any one of claims 11 to 14, wherein the omecamtiv mecarbil dihydrochloride hydrate salt has an x-ray powder diffraction pattern (XRPD) comprising peaks at 6.6, 14.9, 20.1, 21.4, and 26.8 ± 0.2° 2θ using Cu Ka radiation, optionally wherein the x-ray powder diffraction pattern further comprises peaks at 8.4, 24.2, 26.0, and 33.3 ± 0.2° 2θ using Cu Ka radiation, and/or optionally wherein the x-ray powder diffraction pattern further comprises peaks at 6.2, 9.7, 13.2, 14.3, 15.4, 16.3, 16.9, 18.9, 19.5, 20.7, 21.8, 22.8, 23.6, 25.1, 27.3, 27.7, 28.4, 29.4, 30.2, 31.2, 31.5, 31.9, 33.9, 34.5, 34.9, 36.1, 36.8, 37.7, 38.5, and 39.7 ± 0.2° 2θ using Cu Ka radiation. 
Postupak prema bilo kojem od zahtjeva 11 do 14, naznačen time što dihidroklorid hidratna sol omekamtiv mekarbila ima uzorak rendgenske difrakcije na prahu (XRPD) koji sadrži vrhove kod 6.6, 14.9, 20.1, 21.4, 1 26.8 + 0.2" 20 korištenjem Cu Ka zračenja, proizvoljno pri čemu uzorak rendgenske difrakcije na prahu nadalje sadrži vrhove kod 8.4, 24.2, 26.0, i 33.3 + 0.2* 20 korištenjem Cu Ka zračenja, i/ili proizvoljno pri čemu uzorak rendgenske difrakcije na prahu nadalje sadrži vrhove kod 6.2, 9.7, 13.2, 14.3, 15.4, 16.3, 16.9, 18.9, 19.5, 20.7, 0.2* 20 korištenjem Cu Ka zračenja.
A process according to any one of claims 1 to 14, characterised in that by mechanical machining along the lines (6), grooves are introduced into the composite structure which cut through one plate (2, 3), particularly the plate comprising the groove structure (4), and which do not cut through the other plate (2, 3). 
Postupak prema bilo kojem zahtjevu 1 do 14, naznačen time, da se pomoću mehaničke strojne obrade uzduž linija (6) u kompozitnu strukturu uvode brazde, pri čemu se kompozitnu strukturu reže kroz jednu ploču (2, 3), posebno ploču koja ima brazdastu strukturu (4), a ne reže se kroz drugu ploču.
with a vinyl Grignard reagent, to obtain a compound of formula IIa in the form of diastereoisomeric mixture (S,R+R,R) 
S vinil Grignardovim reagensom, da bi se dobio spoj formule Ila u obliku dijastereoizomerne smjese (S, R+R, R)
The composition of any one of claims 8 to 13, wherein the antibody that specifically binds to and neutralizes C. difficile toxin B is a human antibody, a humanized antibody or a chimeric antibody. 
Kompozicija prema bilo kojem od patentnih zahtjeva 8 do 13, naznačena time što antitijelo koje se specifično veže za i neutralizira C. difficile toksin B predstavlja humano antitijelo, humanizirano antitijelo ili himerno antitijelo.
a third separation step S 2 ″ which consists in the separation of fraction F 2 ′ into fraction B and into a fraction F 2 ″. 
- = treći korak odvajanja S2" koji se sastoji u odvajanju frakcije F2' u frakciju B i u frakciju F2".
A neutralising antibody having specificity for human IL-17, having a heavy chain comprising the sequence given in SEQ ID NO:2 and a light chain comprising the sequence given in SEQ ID NO:4. 
Neutralizirajuće antitijelo koje ima specifičnost za ljudski IL-17, naznačeno time da ima teški lanac koji sadrži sekvencu prikazanu u SEQ ID NO:2 1 laki lanac koji sadrži sekvencu prikazanu u SEQ ID NO:4.
A sealed container according to embodiment 11, wherein the modified atmosphere contains increased levels of oxygen or carbon dioxide. 
Posuda prema patentnom zahtjevu 11, pri čemu modifikcirana atmosfera sadrži povećane nivoe kisika ili ugljik dioksida.
The process of claim 39, wherein the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from about 5 mg to about 500 mg of oxycodone hydrochloride. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema zahtjevu 1, naznačen time da je opioidni analgetik oksikodon hidroklorid i da sastav sadrži preko 5 % (težine) oksikodon hidroklorida.
At day 8, the culture was transferred to a RB850 cm2 and diluted to 400 mL by adding fresh and preheated medium SM-005. 
8. dana stanična je kultura prebačena u roler-bocu RB 850 cm i razrijeđena na 400 mL dodatkom svježeg prethodno zagrijanog SM-005 medija.
A compound of Formula (I) a tautomer or a stereoisomeric form thereof, wherein 
Spoj s Formulom (I) tautomer ili njegov stereoizomerni oblik, naznačen time što
Due to high price, and possible carcinogenic effect of hydroxyquinolinolate, USA EPA does not allow registration of this active ingredient. 
Zbog visoke cijene, i mogućeg kancerogenog učinka hidroksikinolinolata, USA EPA ne dozvoljava registraciju ovog aktivnog sastojka.
In a second aspect, the present invention provides a recombinant Von Willebrand Factor (rVWF) composition prepared by a method provided herein. 
Postupak dobivanja pripravka rekombinantnog Von Willebrandovog Čimbenika (rVWF), naznačen time što se postupak sastoji u koracima:
The material was filtered, washed with 20.0 ml of isopropyl alcohol and dried at 60-65° C. for 8 hrs to obtain 10.5 g of nebivolol hydrochloride (I). 
Materijal je profiltriran, ispran s 200 ml izopropil alkohola i osušen na 60-65 "C tijekom 8 sati da bi se dobilo 10,5 g nebivolol hidroklorida (1).
The operation of the circuit is the following. 
Djelovanje kruga je sljedeće.
The immunoassay of claim 29 or the quality assay of claim 30, wherein the bacterial cell is an E . coli cell. The immunoassay of claim 32, wherein the E.coli cell overexpresses DsbA. 
Imunološki test iz patentnog zahtjeva 29, ili test kvalitete iz patentnog zahtjeva 30, naznačen time, da je bakterijska stanica E.coli stanica.
between 0% and about 10% of talc, 
(c) Između 0% i oko 10% talka,
The method according to any of claims 5-9, further comprising any of the features of claim 3, and wherein said rinsing cartridge is pressurized by said enabling pressure, or further comprising said rinsing cartridge being pressurized by said fluid pressure source or said pressure chamber. 
Metoda u skladu sa bilo kojim od patentnih zahtjeva 4-8, gdje je navedeni spremnik za pranje (20,118,132) stavljen pod pritisak pomoću navedenog omogućavajućeg pritiska, ili dalje sadrži navedeni spremnik za pranje (20,118,132) koji je stavljen pod pritisak pomoću spomenutog izvora pritiska fluida (112) ili navedene komore za pritisak (10).
A pharmaceutical composition comprising a compound having the structure shown in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for use in the treatment of a disease or disorder which is selected from multiple myeloma, glioblastoma, and lymphoma. Use of a compound having the structure shown in claim 1 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disease or disorder selected from multiple myeloma, glioblastoma, and lymphoma. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak gušterače. Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak kože. Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bolesti ili poremećaja povezanih sa nekontroliranim, nenormalnim i/ili neželjenim staničnim djelovanjima.
Method of manufacturing the extended release tablet formulation according to one of the preceding claims, via a direct compression process comprising the steps of 
Postupak priprave formulacije tablete produljenog oslobađanja u skladu s jednim od prethodnih zahtjeva 1 do 10, pomoću postupka izravnog komprimiranja, naznačen time, da sadrži slijedeće korake
The present invention therefore relates to atomisers 11 for inhalation purposes which produce a practically stationary aerosol mist or an aerosol mist with a velocity of emergence which is low enough for the propagation of the aerosol mist practically to come to a standstill after a few centimetres. 
Zbog toga se predloženi izum odnosi na atomizere 11 u svrhe inhalacije koji proizvode praktički štacionarnu maglicu aerosola ili maglicu aerosola koja se pojavljuje brzinom koja je dovoljno niska za širenje maglice aerosola tako, da ona praktički dođe u stanje mirovanja nakon nekoliko centimetara.
Use of the pharmaceutical composition according to claim 11 in the preparation of a medicament for the treatment or prevention of autoimmune diseases, inflammatory diseases, cancers, myeloproliferative diseases, bone resorption diseases, graft-versus-host diseases, rheumatoid arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, type I diabetes, allergic diseases, chronic obstructive pulmonary disease, asthma, leukaemia, and lymphoma. 
Korištenje farmaceutskog sastava prema zahtjevu 11 u pripremi lijeka za liječenje ili prevenciju autoimunih bolesti, upalnih bolesti, rakova, mijeloproliferativnih bolesti, bolesti resorpcije kosti, bolesti presatka protiv primatelja, reumatoidnog artritisa, psorijaze, Crohnove bolesti, sistemskog eritemskog lupusa, multiple skleroze, tip I dijabetesa, alergijskih bolesti, kronične opstruktivne plućne bolesti, astme, leukemije 1 limfoma.
The compound of claim 1 that is 1-((2S,5R)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-2-methylpiperidin-1-yl)prop-2-en-1-one, or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 1-((25,5R)-5-(7H-pirolo[2,3-dlpirimidin-4-ilamino)- 2-metilpiperidin-1-il)prop-2-en-1-on, ili njegova farmaceutski prihvatljiva sol.
According to a further subject matter or a further embodiment of the present invention, provision is made for the diameter of the filter element to be greater than the diameter of the capsule base. 
Kapsula s porcijom (1) prema jednom od prethodnih zahtjeva, naznačena time da je promjer elementa filtera (7) veći nego promjer osnovice kapsule (3).
It is also shown by examples that the use of organic acids results, after storing the composition at elevated temperatures, in the production of less impurities in comparison to the use of hydrochloric acid. 
Pomoću primjera također je pokazano da uporaba organskih kiselina u konačnici, nakon što je pripravak skladišten pri povišenim temperaturama, rezultira stvaranjem manje nečistoća u usporedbi sa klorovodičnom kiselinom.
The titled compound is prepared analogously to 1-bromomethyl-2-chloro-4-methanesulfonyl-benzene by replacing 2-chloro-4-fluorobenzaldehyde (step 90a) with 4-fluoro-3-trifluoromethylbenzaldehyde and by replacing sodium methanesulfinate with sodium ethanesulfinate. 
Naslovni spoj je proizveden analogno 1-brom-metil-2-klor-4-metansulfonil-benzenu zamjenom 2-klor-4-fluorbenz-aldehida (stupanj 90a) s 4-fluor-3-trifluormetilbenz-aldehidom 1 zamjenom natrijevog metansulfinata s natrijevim etansulfinatom.
The method of claim 1, wherein said data page has a thickness comprised in a range of about 0.5 mm-0.8 mm. 
Identifikacijski dokument (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je debljina navedene podatkovne stranice (401) u rasponu od oko 0,5 - 0,8 mm.
Process for producing a setting accelerator for a dry mortar blend, the setting accelerator in the form of a powder comprising calcium nitrate, wherein the process comprises the step of spray drying an aqueous solution at least comprising dissolved calcium nitrate, at a temperature between 150° C. and 250° C., into a powder, wherein said powder serves as the setting accelerator and has a water content between 0.1% by weight and 20% by weight and a particle size of 0.1 mm to 1 mm. 
Postupak proizvodnje akceleratora vezivanja za smjesu suhog morta, akcelerator vezivanja je u obliku praška koji sadržava kalcijev nitrat, naznačen time, da postupak obuhvaća korak sušenja raspršivanjem vodene otopine koja sadržava najmanje otopljeni kalcijev nitrat pri temperaturi između 150 *C 1 250 *C, čime se dobiva akcelerator vezivanja koji ima udjel vode između 0,1 % 1 20 %, poželjno između 0,1 % 1 5 %, te veličinu čestica od 0,1 mm do 1 mm.
The composition of any of claims 1 to 6, comprising carbohydrates obtainable from carob, apple, grape and pear. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što sadrži ugljikohidrate koji se mogu dobiti iz rogača, jabuke, grožđa i kruške.
Then, the reaction mixture was cooled and purified preparative HPLC using MeOH/water containing 0.1F TFA (gradient elution). 
Zatim, reakcijska smjesa je hlađena i pročišćena pomoću preparativne HPLC primjenom MeOH/vode koja je sadržavala 0.1F TFA (eluiranje gradijentom).
The floating element in accordance with claim 1, wherein the cavity of the floating element is filled with a buoyancy material. 
Plutajući element (1) prema patentnom zahtjevu 1, naznačen time što je šupljina (3) plutajućeg elementa (1) ispunjena materijalom za uzgon.
A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to Claim 1 wherein: ring A represents furyl, phenyl, pyrazinyl, pyridazinyl, pyridyl, pyrimidinyl, thienyl or thiazolyl ring; 
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time, da: prsten A predstavlja furilni, fenilni, pirazinilni, piridazinilni, piridilni, pirimidinilni, tenilni ili tiazolilni prsten;
The method of claim 1, wherein the endogenous mouse Vλ gene segments have been replaced with a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ3-27 gene segment to a human Vλ3-1 gene segment and a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ5-52 gene segment to a human Vλ1-40 gene segment. 
Miš prema patentnom zahtjevu 1, naznačen time, što lokus endogenog mišjeg lakog lanca K sadrži a) = graničnu sekvencu lokusa humanog lakog lanca koja se proteže od hVA3- 12 do hV23-1; b) graničnu sekvencu lokusa humanog lakog lanca A koja se proteže od hV2A3- 27 do hV23-1; ili c) = graničnu sekvencu lokusa humanog lakog lanca A koja se proteže od hVA5- 52 do hV2A1-40 1 graničnu sekvencu lokusa humanog lakog lanca X koja se proteže od hVA3-29 do hV23-1.
Preferred salts are the aspartate di-salt or the pamoate monosalt. 
Preferirane soli su aspartat disoli ili pamoat mono-sol.
To intermediate (b) is added a solution of trifluoroacetic anhydride (710.3 g, 3.38 mole) in tetrahydrofuran (1.600 mL) slowly over 25 min, and the reaction allowed to warm no greater than 15 °C. The reaction is stirred overnight to provide compound (c). 
Međuproduktu (b) polako se 25 minuta dodaje otopina trifluoracetanhidrida (710,3 g, 3,38 mol) u tetrahidrofuranu (1,600 ml), a reakcijsku smjesu ostavi da se zagrije do najviše 15 *C. Reakcijsku smjesu miješa se preko noći kako bi se dobilo spoj (c).
The composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) fluopiram.
accordingly change a duration of the predetermined time such that the active load will absorb from the candidate signal said predetermined amount of energy. 
odgovarajuću promjenu trajanja zadanog vremena (Tp) tako da aktivni teret (50) apsorbira iz kandidatnog signala (S.) navedenu zadanu količinu energije (E,).
The composition for the use according to claim 9, wherein said disease is selected from squamous cell carcinoma, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, Burkitt's lymphoma, an acute or chronic myelogenous leukemia, promyelocytic leukemia, fibrosarcoma, neuroblastoma, glioma, astrocytoma, schwannomas, fibrosarcoma, rhabdomyosarcoma, osteosarcoma, melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular cancer, teratocarcinoma, other carcinoma of the bladder, breast, colon, kidney, liver, lung, ovary, prostate, pancreas, stomach, cervix, thyroid or skin, other hematopoietic tumors of lymphoid lineage, other hematopoietic tumors of myeloid lineage, other tumors of mesenchymal origin, and other tumors of the central or peripheral nervous system. 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od karcinoma skvamoznih stanica, leukemije, akutne limfoticne leukemije, akutne limfoblastične leukemije, limfoma B-stanica, limfoma T-stanica, Hodgkinovog limfoma, ne-Hodgkinovog limfoma, limfoma dlakavih stanica, Burkettovog limfoma, akutnih ili kroničnih mijeloičnih HR P20120845 T1 leukemija, promijelocitne leukemije, fibrosarkoma, rabdomiosarkoma; melanoma, seminoma, teratokarcinoma, neuroblastoma, glioma, astrocitoma, schwannoma, osteosarkoma, kseroderme pigmentosum, keratoakantoma, raka folikula štitnjače, drugog karcinoma mjehura, dojke, kolona, bubrega, jetre, pluča, jajnika, prostate, gušterače, želuca, cerviksa, štitnjače ili kože, drugih hematopoetskih tumora limfoidne linije, drugih hematopoetskih tumira mijeloične linije, drugih tumora mezenhimskog porijekla, drugih tumora središnjeg ili perifernog živčanog sustava.